ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,724.30
-0.33%
S&P ASX All Technology
3,092.70
-1.13%
Brent Oil
82.275
0.00%
US Dollar vs AUD
1.51378
0.08%
Bitcoin
66,136.51
0.20%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Lipocine Inc (LPCN)

  7. Lipocine Inc (LPCN) News

LPCN

Lipocine (LPCN)

Lipocine Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LPCN
DateTimeSourceHeadlineSymbolCompany
10/06/202423:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
10/06/202422:00PR Newswire (US)Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024NASDAQ:LPCNLipocine Inc
08/06/202407:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
08/06/202407:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
08/06/202407:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
08/06/202407:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
08/06/202407:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
06/06/202406:32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
04/06/202407:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
04/06/202407:09Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:LPCNLipocine Inc
09/05/202422:00PR Newswire (US)Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024NASDAQ:LPCNLipocine Inc
09/05/202420:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LPCNLipocine Inc
09/05/202420:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
08/05/202422:00PR Newswire (US)Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024NASDAQ:LPCNLipocine Inc
08/05/202420:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
01/05/202422:00PR Newswire (US)Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154NASDAQ:LPCNLipocine Inc
11/04/202421:00PR Newswire (US)Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityNASDAQ:LPCNLipocine Inc
28/03/202423:00PR Newswire (US)Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with CirrhosisNASDAQ:LPCNLipocine Inc
25/03/202423:00PR Newswire (US)Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154NASDAQ:LPCNLipocine Inc
08/03/202409:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
08/03/202400:00PR Newswire (US)Lipocine Announces Financial Results for the Full Year Ended December 31, 2023NASDAQ:LPCNLipocine Inc
07/03/202422:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
07/03/202422:07Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LPCNLipocine Inc
07/03/202400:00PR Newswire (US)Lipocine to Present at 36th Annual Roth ConferenceNASDAQ:LPCNLipocine Inc
06/03/202422:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
13/02/202408:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
07/02/202400:00PR Newswire (US)Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154NASDAQ:LPCNLipocine Inc
03/02/202400:00PR Newswire (US)Lipocine Announces Continued Commercialization of TLANDO® through Verity PharmaceuticalsNASDAQ:LPCNLipocine Inc
19/01/202400:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
19/01/202400:00PR Newswire (US)Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and CanadaNASDAQ:LPCNLipocine Inc
 Showing the most relevant articles for your search:NASDAQ:LPCN

Your Recent History

BIT
P1MK53
BNP Paribas Issuance
BIT
P1XOP2
NLBNPIT1XOP2 20991231 9....
COIN
TAIZOETH
Taizo Hori
BIT
P1VM43
NLBNPIT1VM43 20351221 88...
COIN
ONUSD
OFIN TOKEN
TSXV
PSQ.P
P Squared Renewables
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved